Skip to main content
Premium Trial:

Request an Annual Quote

NeuMoDx Gets CE Mark for Cytomegalovirus, Epstein-Barr Virus Tests

NEW YORK – NeuMoDx Molecular said this week that its molecular assays for cytomegalovirus (CMV) and Epstein-Barr virus have received CE-IVD marking and are now commercially available in Europe and other locations that recognize the designation.

NeuMoDx's tests are designed for central laboratory use and run on the company's fully automated NeuMoDx 96 or 288 real-time PCR systems, which provide different levels of throughput. 

Patient samples can be loaded in a continuous random-access manner, resulting in on-demand, high-throughput sample processing with an operator walkway window of up to eight hours and first test results available in about an hour, the company said.

In September, Qiagen and NeuMoDx signed a partnership and merger agreement related to the commercialization of the NeuMoDx test systems. Under the agreement, Qiagen is distributing the systems in Europe and other ex-US markets. Qiagen also owns about 20 percent of Ann Arbor, Michigan-based NeuMoDx, and has the right to acquire all remaining shares for a predetermined price of approximately $234 million, subject to the achievement of regulatory and operational milestones.

The Scan

Billion-Dollar Diversity Initiative

The Howard Hughes Medical Institute is now accepting applications for its new $1.5 billion initiative to boost the diversity of the scientific workforce.

Biotech Co-Founder Arrested

A co-founder of a Los Angeles-based biotech company has been arrested in connection with a murder-for-hire scheme, according to Endpoint News.

Return of the Tasmanian Tiger

The Washington Post reports that a team in Australia is working to bring the thylacine back from extinction.

Nature Papers on Genome of Individual From Pompeii, CircRNA Study Best Practices, More

In Nature this week: first sequenced genome of a person from Pompeii, best practice guidelines for circRNA studies, and more.